Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iowa to track meth precursors

This article was originally published in The Tan Sheet

Executive Summary

Gov. Chet Culver (D) signs a law establishing a real-time electronic repository to monitor sales of ephedrine- and pseudoephedrine-containing products in Iowa. Senate File 237, enacted March 25 and effective July 1, makes Iowa the seventh state to mandate electronic logbooks for purchases of nonprescription methamphetamine precursors, according to the National Association of Chain Drug Stores. Oklahoma, Arkansas, Kentucky and West Virginia actively track PSE sales. Hawaii and Missouri have approved but have yet to implement systems. The Kansas Senate has approved an electronic logbook bill (1"The Tan Sheet" March 16, 2009, In Brief)

You may also be interested in...



Illinois pilot program tracks PSE

Six Illinois counties begin electronically tracking pharmacy purchases of nonprescription products containing pseudoephedrine June 15 as part of a pilot program overseen by the Southern Illinois Enforcement Group. The Illinois State Police Precursor Tracking Program is slated for evaluation after eight months to determine the feasibility of a statewide system for monitoring purchases of methamphetamine precursors. Tom McNamara, special projects coordinator for Carbondale-based SIEG, said in an interview the e-tracking system is online but will not be fully operational until Aug. 17. In March, Iowa became the seventh state to mandate electronic tracking for purchases of meth ingredients (1"The Tan Sheet" April 6, 2009, In Brief)

Kan. Senate votes for meth precursor e-tracking

A statewide system for tracking purchases of nonprescription products containing ephedrine or pseudoephedrine is a step closer to reality after the Kansas Senate passes S.B. 248. Following its March 12 approval by 37-3 margin, the bill will next be considered in the state House. Other states have set up similar electronic logbooks to monitor purchases of methamphetamine precursors - including Tennessee, which says its statewide tracking system has been a success (1"The Tan Sheet" Feb. 2, 2009, p. 4). ... Mo. Senate votes down PSE Rx amendment: An attempt to amend a larger crime bill with a measure requiring a prescription for products containing methamphetamine precursors fails in the Missouri state Senate March 4. The amendment offered by state Sen. Jason Crowell, a Republican representing the Cape Girardeau area, "was soundly defeated" by voice vote, according to a legislature spokesman. Separately, Crowell has sponsored a bill, S.B. 160, to make cough/cold remedies containing ephedrine or pseudoephedrine available by prescription only, which remains viable (2"The Tan Sheet" Feb. 23, 2009, p. 3). A companion bill, H.B. 496, is under consideration in the House and has been passed out of committee

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel